Literature DB >> 29381433

Targeting HER2 by Combination Therapies.

Ana Ruiz-Saenz1, Mark M Moasser1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29381433      PMCID： PMC6053674          DOI： 10.1200/JCO.2017.77.1899

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  70 in total

1.  RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.

Authors:  Peter Littlefield; Mark M Moasser; Natalia Jura
Journal:  Chem Biol       Date:  2014-03-20

Review 2.  Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Pasi A Jänne; Bruce E Johnson
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

3.  The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

Authors:  SaeGwang Park; Zhujun Jiang; Eric D Mortenson; Liufu Deng; Olga Radkevich-Brown; Xuanming Yang; Husain Sattar; Yang Wang; Nicholas K Brown; Mark Greene; Yang Liu; Jie Tang; Shengdian Wang; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

4.  (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  Mol Cancer Ther       Date:  2012-01-11       Impact factor: 6.261

5.  HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.

Authors:  Britta Weigelt; Alvin T Lo; Catherine C Park; Joe W Gray; Mina J Bissell
Journal:  Breast Cancer Res Treat       Date:  2009-08-22       Impact factor: 4.872

6.  A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

Authors:  Si Tuen Lee-Hoeflich; Lisa Crocker; Evelyn Yao; Thinh Pham; Xander Munroe; Klaus P Hoeflich; Mark X Sliwkowski; Howard M Stern
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

7.  Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

Authors:  J Verweij; A van Oosterom; J-Y Blay; I Judson; S Rodenhuis; W van der Graaf; J Radford; A Le Cesne; P C W Hogendoorn; E D di Paola; M Brown; O S Nielsen
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

8.  Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Authors:  Yen-Chao Wang; Gladys Morrison; Ryan Gillihan; Jun Guo; Robin M Ward; Xiaoyong Fu; Maria F Botero; Nuala A Healy; Susan G Hilsenbeck; Gail Lewis Phillips; Gary C Chamness; Mothaffar F Rimawi; C Kent Osborne; Rachel Schiff
Journal:  Breast Cancer Res       Date:  2011-11-28       Impact factor: 6.466

9.  Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.

Authors:  Maurizio Scaltriti; Pieter J Eichhorn; Javier Cortés; Ludmila Prudkin; Claudia Aura; José Jiménez; Sarat Chandarlapaty; Violeta Serra; Aleix Prat; Yasir H Ibrahim; Marta Guzmán; Magui Gili; Olga Rodríguez; Sonia Rodríguez; José Pérez; Simon R Green; Sabine Mai; Neal Rosen; Clifford Hudis; José Baselga
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-14       Impact factor: 11.205

10.  Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging.

Authors:  Kengo Kanazaki; Kohei Sano; Akira Makino; Yoichi Shimizu; Fumio Yamauchi; Satoshi Ogawa; Ning Ding; Tetsuya Yano; Takashi Temma; Masahiro Ono; Hideo Saji
Journal:  Nanomedicine       Date:  2015-07-31       Impact factor: 5.307
View more
  6 in total

1.  Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.

Authors:  Jean-Philippe Coppé; Miki Mori; Bo Pan; Christina Yau; Denise M Wolf; Ana Ruiz-Saenz; Diede Brunen; Anirudh Prahallad; Paulien Cornelissen-Steijger; Kristel Kemper; Christian Posch; Changjun Wang; Courtney A Dreyer; Oscar Krijgsman; Pei Rong Evelyn Lee; Zhongzhong Chen; Daniel S Peeper; Mark M Moasser; René Bernards; Laura J van 't Veer
Journal:  Nat Cell Biol       Date:  2019-06-03       Impact factor: 28.824

2.  Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo.

Authors:  Lu Zhang; Di Jing; Nian Jiang; Tatu Rojalin; Christopher M Baehr; Dalin Zhang; Wenwu Xiao; Yi Wu; Zhaoqing Cong; Jian Jian Li; Yuanpei Li; Lei Wang; Kit S Lam
Journal:  Nat Nanotechnol       Date:  2020-01-27       Impact factor: 40.523

3.  Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model.

Authors:  Wende Li; Sen Li; Ivy X Chen; Yujiao Liu; Rakesh R Ramjiawan; Chi-Ho Leung; Leo E Gerweck; Dai Fukumura; Jay S Loeffler; Rakesh K Jain; Dan G Duda; Peigen Huang
Journal:  Radiat Oncol       Date:  2021-03-04       Impact factor: 3.481

4.  Ultrasound-triggered herceptin liposomes for breast cancer therapy.

Authors:  Amal Elamir; Saniha Ajith; Nour Al Sawaftah; Waad Abuwatfa; Debasmita Mukhopadhyay; Vinod Paul; Mohammad H Al-Sayah; Nahid Awad; Ghaleb A Husseini
Journal:  Sci Rep       Date:  2021-04-06       Impact factor: 4.379

5.  Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A.

Authors:  Soheila Kazemi; Shinsaku Kawaguchi; Christian E Badr; Daphne R Mattos; Ana Ruiz-Saenz; Jeffrey D Serrill; Mark M Moasser; Brian P Dolan; Ville O Paavilainen; Shinya Oishi; Kerry L McPhail; Jane E Ishmael
Journal:  Biochem Pharmacol       Date:  2020-11-03       Impact factor: 5.858

6.  Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations.

Authors:  Pier Selenica; Barbara Alemar; Cathleen Matrai; Karen L Talia; Emanuela Veras; Yaser Hussein; Esther Oliva; Regina G H Beets-Tan; Yoshiki Mikami; W Glenn McCluggage; Takako Kiyokawa; Britta Weigelt; Kay J Park; Rajmohan Murali
Journal:  Mod Pathol       Date:  2020-12-14       Impact factor: 8.209
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.